Radiation Therapy Overcomes Immunotherapy Resistance in Some Cancers
“By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to the treatment, leading to positive outcomes for patients, according to new research by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Netherlands Cancer Institute.”
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
“CHICAGO, July 28, 2025–(BUSINESS WIRE)–MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor.”
Alcohol-related disorders are associated with short-term outcomes in lung cancer patients undergoing VATS lobectomy: a 5-year retrospective analysis
“Our findings reveal the substantial effect of alcohol exposure on short-term outcomes for lung cancer patients undergoing VATS lobectomy. The adverse influences of alcohol abuse/dependence were particularly pronounced in this surgical context. These results emphasize the necessity for preoperative risk stratification in these high-risk patients.”
COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment
“The regimen of amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) is known to have dermatologic adverse effects (AEs) that can make staying on treatment a challenge. Investigators in the phase 2 COCOON trial (NCT06120140) set out to find a way to mitigate dermatologic AEs that patients with non–small cell lung cancer (NSCLC)may experience when receiving the regimen.”
Validation of a rapid biomarker assay for lung cancer using the IntelliPlex panel
“A large proportion of non-small-cell lung cancer (NSCLC) patients harbor clinically actionable genomic alterations, detected in general by broad Next-Generation Sequencing (NGS) panels, since it is the gold standard test and strongly recommended by different societies. However, high failure rates due to preanalytical factors and long turnaround times are still hindering rapid treatment decision taking in the real-world setting.”
Night Shift Work Tied to Elevated Lung Cancer Risk, Especially Among Smokers
“Compared with day workers, those working rotating shifts with usual or permanent night shifts had an 84% higher risk of developing lung cancer.”
FDA Fast Tracks DB-1310 for Advanced Nonsquamous Lung Cancer
“Key Takeaways: DB-1310, a HER3-targeting ADC, received FDA fast track designation for advanced nonsquamous non-small cell lung cancer with specific EGFR mutations. Early trials demonstrated promising efficacy and manageable safety, with a 43.5% confirmed overall response rate and 91.3% disease control rate.”
